Hepatic tumor growth: target for angiogenesis inhibition?
Pathologic angiogenesis induced by a tumor is essential for its survival. The promise of tumor inhibition by targeting angiogenesis over the past several years has translated into numerous ongoing clinical trials. Recently, in a phase III trial involving patients with metastatic colorectal cancer, Bevacizumab (Genentech, Inc, San Francisco, CA), a recombinant humanized monoclonal antibody against vascular endothelial growth factor used in conjunction with standard chemotherapy was shown to increase survival, progression-free survival, response rate, and duration of response compared to chemotherapy alone. Thus far, duration of the increased response remains less than 6 months. The majority of deaths in patients with colorectal cancer are related to hepatic metastases. It is hoped that novel approaches directed at the complex interactions between tumor and microenvironment in the angiogenic process will strengthen the therapeutic armamentarium against hepatic malignancies.
Sarraf-Yazdi
Shiva
S
Department of Surgery, Duke University Medical Center, DUMC, 3247, Durham, N.C. 27710, USA.
Mi
Jing
J
Clary
Bryan M
BM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D042682:Angiopoietins / Q000502:physiology; D000911:Antibodies, Monoclonal / Q000502:physiology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D042787:Receptor, TIE-2 / Q000502:physiology
D020533:Angiogenesis Inhibitors; D042682:Angiopoietins; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D042787:Receptor, TIE-2